This table will no longer be updated after 5/30/2024 given the end of the 2023-2024 viral respiratory vaccine season. This table shows the number of CT residents who received an updated 2023-2024 COVID-19 vaccination by week and age group (current age). Only the first dose is counted. CDC recommends that people get at least one dose of this vaccine to protect against serious illness, whether or not they have had a COVID-19 vaccination before. Children and people with moderate to severe immunosuppression might be recommended more than one dose. For more information on COVID-19 vaccination recommendations, click here. • Data are reported weekly on Thursday and include doses administered to Saturday of the previous week (Sunday – Saturday). All data in this report are preliminary. Data from the previous week may be changed because of delays in reporting, deduplication, or correction of errors. • These analyses are based on data reported to CT WiZ which is the immunization information system for CT. CT providers are required by law to report all doses of vaccine administered. CT WiZ also receives records on CT residents vaccinated in other jurisdictions and by federal entities which share data with CT Wiz electronically. Electronic data exchange is being added jurisdiction-by-jurisdiction. Currently, this includes Rhode Island and New York City but not Massachusetts and New York State. Therefore, doses administered to CT residents in neighboring towns in Massachusetts and New York State will not be included. A full list of the jurisdiction with which CT has established electronic data exchange can be seen at the bottom of this page (https://portal.ct.gov/immunization/Knowledge-Base/Articles/Vaccine-Providers/CT-WiZ-for-Vaccine-Providers-and-Training/Query-and-Response-functionality-in-CT-WiZ?language=en_US) • People are included if they have an active jurisdictional status in CT WiZ at the time weekly data are pulled. This excludes people who live out of state, are deceased and a small percentage who have opted out of CT WiZ.

Community specific data reports for vaccine administration results, updated weekly, and data from the Public Health (DPH) COVID Community Impact Survey to help target approaches.

Access available resources below such as data reports, and Public Health Council presentations.

Information about school immunization requirements and data

BackgroundThe Latin American and Caribbean (LAC) region has been one of the regions most affected by the COVID-19 pandemic, with countries presenting some of the highest numbers of cases and deaths from this disease in the world. Despite this, vaccination intention is not homogeneous in the region, and no study has evaluated the influence of the mass media on vaccination intention. The objective of this study was to evaluate the association between the use of mass media to learn about COVID-19 and the non-intention of vaccination against COVID-19 in LAC countries.MethodsAn analysis of secondary data from a Massachusetts Institute of Technology (MIT) survey was conducted in collaboration with Facebook on people's beliefs, behaviors, and norms regarding COVID-19. Crude and adjusted prevalence ratios (aPR) with their respective 95% confidence intervals (95%CI) were calculated to evaluate the association between the use of mass media and non-vaccination intention using generalized linear models of the Poisson family with logarithmic link.ResultsA total of 350,322 Facebook users over the age of 18 from LAC countries were included. 50.0% were men, 28.4% were between 18 and 30 years old, 41.4% had a high school education level, 86.1% lived in the city and 34.4% reported good health condition. The prevalence of using the mass media to learn about COVID-19 was mostly through mixed media (65.8%). The non-intention of vaccination was 10.8%. A higher prevalence of not intending to be vaccinated against COVID-19 was found in those who used traditional media (aPR = 1.36; 95%CI: 1.29–1.44; p < 0.001) and digital media (aPR = 1.70; 95%CI: 1.24–2.33; p = 0.003) compared to those using mixed media.ConclusionWe found an association between the type of mass media used to learn about COVID-19 and the non-intention of vaccination. The use of only traditional or digital information sources were associated with a higher probability of non-intention to vaccinate compared to the use of both sources.

This open dataset shows data on Cambridge residents who have received a COVID-19 vaccine at any location (e.g., mass vaccination site, pharmacy, doctor's office). These data come from the Massachusetts Department of Public Health's weekly report on vaccine doses administered by municipality. The report is released on Thursdays. This open dataset includes data going back several weeks and complements another open dataset called "Cambridge Vaccine Demographics," which shows data for the latest week (https://data.cambridgema.gov/Public-Health/Cambridge-Vaccination-Demographics/66td-u88k)

The Moderna and Pfizer vaccines require two doses administered at least 28 days apart in order to be fully vaccinated. The J&J (Janssen) vaccine requires a single dose in order to be fully vaccinated.

The category "Residents Who Received at Least One Dose" reflects the total number of individuals in the fully and partially vaccinated categories. That is, this category comprises individuals who have received one or both doses of the Moderna/Pfizer vaccine or have received the single dose J&J (Janssen) vaccine.

The category "Fully Vaccinated Residents" comprises individuals who have received both doses of the Moderna/ Pfizer vaccine or the single-dose J&J vaccine.

The category "Partially Vaccinated Residents" comprises individuals who have received only the first dose of the Moderna/Pfizer vaccine.

Source: Weekly COVID-19 Municipality Vaccination Report. Massachusetts releases updated data each Thursday at 5 p.m.

Splitgraph serves as an HTTP API that lets you run SQL queries directly on this data to power Web applications. For example:

See the Splitgraph documentation for more information.

View daily updates and historical trends for Massachusetts Coronavirus Full Vaccination Rate. Source: Our World in Data. Track economic data with YCharts …

Mass Vaccination Clinic Software Market Outlook

According to our latest research, the global Mass Vaccination Clinic Software market size reached USD 1.29 billion in 2024, reflecting robust adoption across healthcare systems worldwide. The market is poised to expand at a CAGR of 13.8% from 2025 to 2033, driven by digital transformation in public health and the rising need for efficient immunization management. By 2033, the market is forecasted to reach USD 4.11 billion. The key growth factor fueling this expansion is the increasing demand for streamlined, scalable, and secure solutions to manage large-scale vaccination drives, particularly in response to global health emergencies and routine immunization programs.

A primary driver of the Mass Vaccination Clinic Software market is the growing emphasis on public health preparedness and rapid response to pandemics. The COVID-19 pandemic underscored the necessity for robust digital infrastructure capable of managing unprecedented vaccination volumes, scheduling, supply chain logistics, and real-time reporting. Governments and healthcare organizations are investing heavily in advanced software platforms that can automate registration, consent, inventory tracking, and follow-up reminders. This shift towards digitization ensures not only operational efficiency but also enhances patient safety and data integrity. Additionally, the integration of analytics and artificial intelligence with mass vaccination clinic software enables authorities to monitor vaccine coverage, identify gaps, and optimize resource allocation, further driving market growth.

Another significant growth factor is the expanding scope of immunization programs beyond COVID-19. With increasing incidences of seasonal influenza, measles outbreaks, and the introduction of new vaccines for diseases such as HPV and meningitis, healthcare providers are seeking comprehensive solutions that can support multiple vaccination campaigns simultaneously. The ability of mass vaccination clinic software to handle diverse immunization schedules, manage multi-dose regimens, and ensure compliance with regulatory standards makes it indispensable for large-scale public health initiatives. Furthermore, collaborations between public and private sectors, coupled with funding from international health organizations, are accelerating software adoption in both developed and emerging markets.

The proliferation of cloud-based deployment models is also propelling the Mass Vaccination Clinic Software market. Cloud solutions offer scalability, remote access, and seamless integration with existing health information systems, making them ideal for geographically dispersed vaccination sites and mobile clinics. These platforms facilitate real-time data sharing and interoperability, enabling coordinated efforts across multiple stakeholders including hospitals, pharmacies, community health centers, and government agencies. As cybersecurity and data privacy regulations become more stringent, vendors are investing in advanced security features and compliance certifications, further boosting market confidence and adoption rates.

In the realm of digital solutions for healthcare, Travel Vaccine Management Software is emerging as a pivotal tool. This software is designed to streamline the process of administering vaccines to travelers, ensuring that they receive the necessary immunizations before visiting specific regions. With the increasing globalization and the rise in international travel, there is a growing need for efficient systems that can manage vaccine schedules, track patient histories, and provide reminders for upcoming doses. Travel Vaccine Management Software not only aids healthcare providers in maintaining comprehensive records but also enhances patient engagement by offering easy access to vaccination information. As more people venture abroad, the demand for such specialized software is expected to rise, contributing to the broader landscape of vaccination management solutions.

Regionally, North America continues to lead the global market, accounting for the largest share in 2024, followed by Europe and Asia Pacific. This dominance is attributed to the presence of advanced healthcare infrastructure, high digital literacy, and proactive government initiatives for mass immunization. However, Asia Pacific is anticipated to witness the highest CAGR over the forecast period, dri

Respondents’ opinion on acceptance of COVID-19 vaccine.

United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: N/A data was reported at 13.200 % in 11 Apr 2022. This records a decrease from the previous number of 14.100 % for 04 Apr 2022. United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: N/A data is updated weekly, averaging 14.050 % from Nov 2021 (Median) to 11 Apr 2022, with 18 observations. The data reached an all-time high of 19.100 % in 14 Mar 2022 and a record low of 9.000 % in 22 Nov 2021. United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: N/A data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.S049: Small Business Pulse Survey: by State: Northeast Region: Weekly, Beg Monday (Discontinued).

This open dataset shows data on Cambridge residents who have received a COVID-19 vaccine at any location (e.g., mass vaccination site, pharmacy, doctor's office). These data come from the Massachusetts Department of Public Health's weekly report on vaccine doses administered by municipality. The report is released on Thursdays.

The Moderna and Pfizer vaccines require two doses administered at least 28 days apart in order to be fully vaccinated. The J&J (Janssen) vaccine requires a single dose in order to be fully vaccinated.

The category "Residents Who Received at Least One Dose" reflects the total number of individuals in the fully and partially vaccinated categories. That is, this category comprises individuals who have received one or both doses of the Moderna/Pfizer vaccine or have received the single dose J&J (Janssen) vaccine.

The category "Fully Vaccinated Residents" comprises individuals who have received both doses of the Moderna/ Pfizer vaccine or the single-dose J&J vaccine.

The category "Partially Vaccinated Residents" comprises individuals who have received only the first dose of the Moderna/Pfizer vaccine.

Source: Weekly COVID-19 Municipality Vaccination Report. Massachusetts releases updated data each Thursday at 5 p.m.

Splitgraph serves as an HTTP API that lets you run SQL queries directly on this data to power Web applications. For example:

See the Splitgraph documentation for more information.

United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: No data was reported at 77.600 % in 11 Apr 2022. This records an increase from the previous number of 73.900 % for 04 Apr 2022. United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: No data is updated weekly, averaging 72.700 % from Nov 2021 (Median) to 11 Apr 2022, with 18 observations. The data reached an all-time high of 77.600 % in 11 Apr 2022 and a record low of 65.500 % in 03 Jan 2022. United States SB: MA: COVID Test/Vaccine: Proof of COVID Vaccination: No data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.S049: Small Business Pulse Survey: by State: Northeast Region: Weekly, Beg Monday (Discontinued).

View daily updates and historical trends for Massachusetts Coronavirus Vaccination Rate: Any Dosage. Source: Our World in Data. Track economic data with Y…

Flyer for mass COVID vaccine clinic on 4-16-2021

While mass vaccination campaigns against COVID-19 have inoculated almost 200 million Americans and billions more worldwide, significant pockets of vaccine hesitancy remain. Research has firmly established that vaccine efficacy is an important driver of public vaccine acceptance and choice. However, current vaccines offer widely varying levels of protection against different adverse health outcomes of COVID-19. This study employs an experiment embedded on a survey of 1,194 US adults in June 2021 to examine how communications about vaccine efficacy affect vaccine choice. The experiment manipulated how vaccine efficacy was defined across four treatments: (1) protection against symptomatic infection; (2) protection against severe illness; (3) protection against hospitalization/death; (4) efficacy data on all three metrics. The control group received no efficacy information. Subjects were asked to choose between a pair of vaccines—a one-dose viral vector vaccine or two-dose mRNA vaccine—whose efficacy data varied across the four experimental treatment groups. Efficacy data for each vaccine on each dimension were adapted from clinical trial data on the Johnson & Johnson/Janssen and Pfizer/BioNTech vaccines. Among all respondents, only modest preference gaps between the two vaccines emerged in the control group and when the two vaccines’ roughly equivalent efficacy data against hospitalization and death were reported. Strong preferences for a two-dose mRNA vaccine emerged in treatments where its higher efficacy against symptomatic or severe illness was reported, as well as in the treatment where data on all three efficacy criteria were reported. Unvaccinated respondents preferred a one-dose viral vector vaccine when only efficacy data against hospitalization or death was presented. Black and Latino respondents were significantly more likely to choose the one-shot viral vector vaccine in the combined efficacy treatment than were whites. Results speak to the importance of understanding how communications about vaccine efficacy affect public preferences in an era of increasing uncertainty about efficacy against variants.

Logistic regression on respondents’ knowledge of COVID-19 vaccination.

The overall goal for this project was to reduce the incidence of COVID-19, hospitalization, and mortality among adults with serious mental illness (SMI) and intellectual disabilities/developmental disabilities (IDD) in congregate living settings (i.e., group homes) in Massachusetts, as well as to reduce COVID-19 incidence among staff who work in these settings. The research team was guided by two comparative effectiveness questions: With the goal of prioritizing and making actionable best practices available as resources, what is the comparative effectiveness of various types and intensities of preventative interventions (e.g., screening, isolation, contact tracing, hand hygiene, physical distancing, use of face masks) in reducing rates of COVID-19, related hospitalizations, and related mortality in this population? With the goal of effectively implementing best practices, what is the most effective implementation strategy to reduce rates of COVID-19 in this population: using tailored best practices (TBP) with SMI/IDD residents and staff of group homes in mind, or general best practices (GBP) from state and federal standard guidelines for all congregate care settings? The specific aims of this study were as follows: Aim 1a. Synthesize existing baseline data collected by 6 state behavioral health agencies on COVID-19 rates, hospitalization, mortality, and use of infection prevention practices. Aim 1b. Collect stakeholder input via surveys and virtual focus groups on staff and resident experiences and on barriers/facilitators to implementing recommended preventative practices. Aims 2a and 2b. Determine the comparative effectiveness of various COVID-19 preventative practices by (Aim 2a) using a validated simulation model to estimate COVID-19 spread in group homes and (Aim 2b) obtaining stakeholder input on prioritizing and defining tailored best practices for implementation. Aim 3. Compare the effectiveness of TBPs with GBPs by using a hybrid effectiveness-implementation cluster randomized controlled trial. Data collected to answer Aims 1 and 2 served as the foundation for designing the Aim 3 trial. Data for the trial were collected in 3-month intervals beginning January 2021 (baseline) until October 2022 (15-month follow-up). Residents and staff were sampled from approximately 400 group homes. Primary implementation outcome measures were COVID-19 vaccination rates and fidelity scores. The primary effectiveness outcome measure was COVID-19 infection. Notes: This collection contains only data from Aim 1a and Aim 3. Throughout the data and documentation, "intellectual and/or developmental disabilities" is abbreviated as both IDD and ID/DD.

Background: The COVID-19 pandemic is our generation's greatest global challenge to our public health system. Vaccines are considered one of the most effective tools available for preventing COVID-19 infection and its complications and sequelae. Understanding and addressing the psychological stress related to COVID-19 vaccination may promote acceptance of these vaccines.Methods: We conducted an online survey from January 29 to April 26, 2021 to explore stress levels related to COVID-19 vaccination among the general public in China. Participants were asked to evaluate their psychological stress of considering whether or not to get vaccinated at the beginning period of the COVID-19 mass vaccination, after getting access to the information about the vaccine, as well as after getting vaccinated, using visual analog stress scale. Multiple linear regression analysis was performed to explore factors potentially associated with COVID-19-related psychological stress levels before and after getting vaccinated.Results: A total of 34,041 participants were included in the final analysis. The mean stress score concerning COVID-19 vaccination was 3.90 ± 2.60 among all participants, and significantly decreased over time. In addition, the vaccine-related stress level significantly decreased after accessing information about the COVID-19 vaccine (N = 29,396), as well as after getting vaccinated (N = 5,103). Multivariable regression analysis showed higher stress levels related to COVID-19 vaccination in participants who were younger, having lower education level, having history of chronic diseases, mistrusting vaccine's efficacy, experience of vaccine allergy events, being affected by the COVID-19 epidemic, and having mental illness symptoms. Moreover, mistrust in vaccine efficacy and experience of vaccine allergy events had a long-term impact on psychological stress levels about COVID-19 vaccination even after getting vaccinated.Conclusions: The current findings profiled the COVID-19 vaccine-related psychological stress among the general public in China. Population-specific management and interventions targeting the stress related to COVID-19 vaccination are needed to help governments and policy makers promote individual's willingness to get vaccinations for public well-being during the COVID-19 pandemic.

Healthcare workers are at the frontline of the COVID-19 pandemic and have been identified as a priority target group for COVID-19 vaccines. This study aimed to determine the COVID-19 vaccination intention among nurses and midwives in Cyprus and reveal the influential factors that affected their decision. An Internet-based cross-sectional survey was conducted between December 8 and 28, 2020. Data collection was accomplished using a self-administered questionnaire with questions about socio-demographic characteristics, questions assessing general vaccination-related intentions and behaviors, and the intention to accept COVID-19 vaccination. A sample of 437 responders answered the survey, with 93% being nurses and 7% midwives. A small proportion of the participants would accept a vaccine against COVID-19, while 70% could be qualified as “vaccine hesitant.” The main reasons for not receiving the COVID-19 vaccine were concerns about the vaccine's expedited development and fear of side effects. More females, individuals with a larger median age, and a higher number of years of working experience, intended to accept the COVID-19 vaccination, compared with those not intended to accept and undecided groups (p < 0.01). Having a seasonal flu vaccination in the last 5 years, receiving the vaccines recommended for health professionals, and working in the private sector were associated with a higher probability of COVID-19 vaccination acceptance. A considerable rate of nurses and midwives in Cyprus reported unwillingness to receive a COVID-19 vaccine due to vaccine-related concerns. Our findings highlight the need for forthcoming vaccination campaigns and programs to tackle coronavirus vaccine hesitancy barriers to achieve the desirable vaccination coverage.

Mass Vaccination Clinic Software Market Outlook

According to our latest research, the global mass vaccination clinic software market size reached USD 1.42 billion in 2024, driven by the ongoing demand for efficient immunization management and digital transformation in healthcare. The market is poised for robust expansion, projected to grow at a CAGR of 13.8% from 2025 to 2033. By 2033, the market is forecasted to attain a value of USD 4.18 billion, reflecting the increasing adoption of digital solutions for mass immunization campaigns, particularly in response to public health emergencies and the growing focus on preventive healthcare. This growth is underpinned by the rising need for streamlined vaccine administration, data management, and reporting capabilities among healthcare providers worldwide.

A key driver propelling the mass vaccination clinic software market is the global emphasis on public health preparedness and rapid response to infectious disease outbreaks. The COVID-19 pandemic has highlighted the necessity for robust digital platforms that can manage large-scale vaccination campaigns efficiently. Governments and health organizations have accelerated their investments in technology to support vaccination logistics, appointment scheduling, inventory management, and real-time data tracking. This has resulted in an unprecedented surge in demand for mass vaccination clinic software, as these platforms facilitate seamless coordination among healthcare professionals, reduce administrative burdens, and ensure accurate record-keeping. The integration of analytics and reporting tools further enhances the ability of authorities to monitor vaccination progress and coverage, ultimately improving public health outcomes.

Another significant growth factor is the increasing adoption of cloud-based solutions in the healthcare sector. Cloud-based mass vaccination clinic software offers scalability, accessibility, and cost-effectiveness, making it an attractive option for organizations of all sizes. These platforms enable healthcare providers to access real-time data from multiple locations, streamline patient registration and consent processes, and ensure compliance with regulatory requirements. The flexibility of cloud deployment supports rapid implementation and integration with other healthcare systems, such as electronic health records (EHRs) and national immunization registries. As healthcare organizations prioritize digital transformation, the shift towards cloud-based solutions is expected to accelerate, further driving the expansion of the mass vaccination clinic software market.

The market is also experiencing growth due to the increasing awareness of the importance of routine immunization and preventive healthcare. Beyond pandemic response, governments and health agencies are investing in digital solutions to manage routine vaccination programs for diseases such as influenza, measles, and polio. The ability of mass vaccination clinic software to automate appointment scheduling, track vaccine inventory, and generate comprehensive reports is critical for improving vaccine coverage rates and ensuring timely administration. Additionally, the rise of community health initiatives and the involvement of non-traditional providers, such as pharmacies and community health centers, are broadening the end-user base for these solutions. This diversification of application areas is expected to sustain long-term growth in the market.

From a regional perspective, North America currently holds the largest share of the mass vaccination clinic software market, supported by advanced healthcare infrastructure, high digital literacy, and proactive government initiatives. Europe follows closely, with significant investments in public health digitization and cross-border immunization efforts. The Asia Pacific region is anticipated to witness the fastest growth during the forecast period, driven by increasing healthcare expenditure, expanding immunization programs, and the adoption of digital health solutions in emerging economies. Latin America and the Middle East & Africa are also showing promising growth trajectories, albeit from a smaller base, as governments in these regions prioritize public health modernization and disease prevention.

Deployment Mode Analysis

The deployment mode segment of the mass vaccination clinic software market is bifurcated into cloud-based and on-premises solutions, each addressing distinct organizational nee